Cargando...
Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data
Patients with type 2 diabetes mellitus (T2DM) are at high risk for cardiovascular (CV) disease; however, conclusive evidence that glycemic control leads to improved cardiovascular outcomes is lacking. Saxagliptin is a potent, selective dipeptidyl peptidase-4 inhibitor approved as an adjunct to diet...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
BioMed Central
2012
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3277488/ https://ncbi.nlm.nih.gov/pubmed/22248301 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1475-2840-11-6 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|